Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionEQ ADVISORS TRUST - EQ/Morgan Stanley Small Cap Growth Portfolio Class IB
Latest Disclosed Ownership15,688 shares
Latest Disclosed Value $ 388,434
EQ ADVISORS TRUST - EQ/Morgan Stanley Small Cap Growth Portfolio Class IB reports 7.70% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 26, 2026 - EQ ADVISORS TRUST - EQ/Morgan Stanley Small Cap Growth Portfolio Class IB filed a NPORT-P form disclosing ownership of 15,688 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $388,435 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 27, 2026 disclosing 16,996 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -7.70% during the quarter. The current value of the position is $494,015 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-26 2026-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 15,688 -1,308 -7.70 388 -2.02 0.1005
2026-02-27 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,996 -1,105 -6.10 397 11.24 0.0930
2025-11-25 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 18,101 -666 -3.55 357 -12.53 0.0759
2025-08-26 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 18,767 1,389 7.99 407 -3.33 0.0943
2025-05-23 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 17,378 600 3.58 421 20.29 0.1111
2025-02-27 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,778 1,049 6.67 350 12.18 0.0805
2024-11-27 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 15,729 -670 -4.09 313 22.83 0.0807
2024-08-26 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 16,399 -7 -0.04 254 -2.68 0.0696
2024-05-23 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,406 817 5.24 262 -0.38 0.0659
2024-02-27 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 15,589 -373 -2.34 262 40.86 0.0661
2023-11-27 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 15,962 1,145 7.73 187 -6.53 0.0526
2023-08-25 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 14,817 495 3.46 199 -16.03 0.0495
2023-05-30 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 14,322 -461 -3.12 237 -13.50 0.0637
2023-03-01 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 14,783 -819 -5.25 275 37.00 0.0817
2022-11-28 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 15,602 53 0.34 200 85.19 0.0557
2022-08-24 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 15,549 -8,292 -34.78 109 -0.92 0.0295
2021-05-28 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 23,841 3,549 17.49 110 62.69 0.0156
2021-02-24 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 20,292 0 0.00 68 11.67 0.0106
2020-11-27 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 20,292 1,217 6.38 60 -31.82 0.0127
2020-08-25 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 19,075 3,318 21.06 88 46.67 0.0208
2020-05-28 2020-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 15,757 506 3.32 61 5.26 0.0235
2020-02-24 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 15,251 0 0.00 57 -28.75 0.0174
2019-11-27 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 15,251 15,251 81 0.0268
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.